These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 10545714)
41. [Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives]. Delvaux M; Frexinos J Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C42-53. PubMed ID: 11787379 [No Abstract] [Full Text] [Related]
42. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Elsenbruch S Brain Behav Immun; 2011 Mar; 25(3):386-94. PubMed ID: 21094682 [TBL] [Abstract][Full Text] [Related]
43. New and future drugs in nerve-gut dysfunction. Bueno L Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):794-801. PubMed ID: 10730572 [TBL] [Abstract][Full Text] [Related]
44. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Crowell MD Br J Pharmacol; 2004 Apr; 141(8):1285-93. PubMed ID: 15100164 [TBL] [Abstract][Full Text] [Related]
45. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. Callahan MJ J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S58-67. PubMed ID: 12184141 [TBL] [Abstract][Full Text] [Related]
46. Sensory dysfunction and the irritable bowel syndrome. Houghton LA Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):415-27. PubMed ID: 10580918 [TBL] [Abstract][Full Text] [Related]
47. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. Mangel AW; Hahn BA; Heath AT; Northcutt AR; Kong S; Dukes GE; McSorley D J Int Med Res; 1998; 26(2):76-81. PubMed ID: 9602985 [TBL] [Abstract][Full Text] [Related]
48. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Gershon MD Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():15-30. PubMed ID: 10429737 [TBL] [Abstract][Full Text] [Related]
49. Serotonin and its implication for the management of irritable bowel syndrome. Gershon MD Rev Gastroenterol Disord; 2003; 3 Suppl 2():S25-34. PubMed ID: 12776000 [TBL] [Abstract][Full Text] [Related]
51. Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome. Galligan JJ Br J Pharmacol; 2004 Apr; 141(8):1294-302. PubMed ID: 15051631 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088 [TBL] [Abstract][Full Text] [Related]
53. Role of serotonin in gastrointestinal physiology and pathology. Cirillo C; Vanden Berghe P; Tack J Minerva Endocrinol; 2011 Dec; 36(4):311-24. PubMed ID: 22322654 [TBL] [Abstract][Full Text] [Related]
54. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis. Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227 [TBL] [Abstract][Full Text] [Related]
55. Review article: evaluation of drugs in experimental gut distension models. Pappas TN; Mangel AW; Lawson C Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741 [TBL] [Abstract][Full Text] [Related]
57. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Zou BC; Dong L; Wang Y; Wang SH; Cao MB Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178 [TBL] [Abstract][Full Text] [Related]